Therefore, this suggests that treatment with platinum should be avoided after olaparib failure, although clinical studies have so far not shown a decreased response to platinum after the resistance of PARP inhibitor in ovarian cancer [27]. The gene discussed is PARP1; the disease is ovarian cancer.